{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:29:42Z","timestamp":1786559382083,"version":"build-2736575974"},"reference-count":85,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023673","name":"Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2601"],"award-info":[{"award-number":["IMSIU-DDRSP2601"]}],"id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Pyruvate kinase (PKLR) is a key glycolytic enzyme that regulates red blood cell energy homeostasis. Although Mitapivat is the first approved allosteric activator for pyruvate kinase deficiency (PKD), its clinical utility is limited by metabolic and pharmacokinetic challenges, underscoring the need for improved analogues. This study aimed to identify novel Mitapivat-derived scaffolds with enhanced PKLR binding, stability, and drug-like properties using an integrated computational approach. A total of 190 structurally related derivatives were screened through molecular docking, pharmacophore modeling, frontier molecular orbital (HOMO\u2013LUMO) analysis, 200 ns molecular dynamics (MD) simulations, MM\/PBSA free energy calculations, ADMET profiling, and retrosynthetic feasibility assessment. Comparative analyses were performed against Mitapivat and phenylalanine, an endogenous PKLR inhibitor. Among the screened compounds, CHEMBL3729403 and CHEMBL3729860 emerged as the most promising candidates. CHEMBL3729403 exhibited the strongest docking affinity (\u22129.10 kcal\/mol) and superior MD stability, with the lowest average RMSD (0.419 nm) and highest hydrogen-bond occupancy (1.039). MM\/PBSA calculations revealed stronger binding free energies for CHEMBL3729403 (\u221226.39\u2009\u00b1\u20093.21 kcal\/mol) and CHEMBL3729860 (\u221223.05\u2009\u00b1\u20093.59 kcal\/mol) than Mitapivat (\u221221.35\u2009\u00b1\u20093.46 kcal\/mol) and phenylalanine (\u22123.89\u2009\u00b1\u20093.91 kcal\/mol). Pharmacophore analysis demonstrated conservation of the key interaction features required for PKLR activation, while HOMO\u2013LUMO analysis revealed comparable electronic characteristics across the lead compounds, supporting their compatibility with ligand\u2013protein interactions. ADMET profiling predicted favorable oral absorption (81.5% and 81.3%), good intestinal permeability, acceptable drug-likeness, and the absence of predicted mutagenic, tumorigenic, reproductive, or irritant liabilities for CHEMBL3729403 and CHEMBL3729860. Retrosynthetic analysis further supported their synthetic accessibility through feasible sulfonamide-coupling routes. Overall, CHEMBL3729403 and CHEMBL3729860 were identified as promising putative PKLR activators with improved predicted binding, stability, and pharmacokinetic properties compared with Mitapivat. These findings warrant further experimental validation to confirm their therapeutic potential in PKD and related metabolic disorders.<\/jats:p>","DOI":"10.1371\/journal.pone.0352669","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:48:24Z","timestamp":1786556904000},"page":"e0352669","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["From structural insight to molecule: Integrative molecular simulations identify candidate pyruvate kinase activators"],"prefix":"10.1371","volume":"21","author":[{"given":"Doni","family":"Dermawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8709-8710","authenticated-orcid":true,"given":"Nasser","family":"Alotaiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"5","key":"pone.0352669.ref001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ajh.27644","article-title":"Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease","volume":"100","author":"MJM Traets","year":"2025","journal-title":"Am J Hematol"},{"issue":"5","key":"pone.0352669.ref002","article-title":"Pyruvate kinase deficiency and PKLR gene mutations: Insights from molecular dynamics simulation analysis","volume":"10","author":"Y Wang","year":"2024","journal-title":"Heliyon"},{"key":"pone.0352669.ref003","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-39956-2.00037-6","article-title":"Pallor and Anemia","volume-title":"Nelson Pediatric Symptom-Based Diagnosis","author":"AM Brandow","year":"2018"},{"key":"pone.0352669.ref004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/JBM.S353907","article-title":"Pyruvate Kinase Deficiency: Current Challenges and Future Prospects","volume":"13","author":"B Fattizzo","year":"2022","journal-title":"J Blood Med"},{"key":"pone.0352669.ref005","doi-asserted-by":"crossref","first-page":"20406207211066070","DOI":"10.1177\/20406207211066070","article-title":"Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias","volume":"12","author":"H Al-Samkari","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"15","key":"pone.0352669.ref006","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa2116634","article-title":"Mitapivat versus Placebo for Pyruvate Kinase Deficiency","volume":"386","author":"H Al-Samkari","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0352669.ref007","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.2023021167","article-title":"Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease","volume":"143","author":"DS Parekh","year":"2024","journal-title":"Blood"},{"key":"pone.0352669.ref008","doi-asserted-by":"crossref","first-page":"101165","DOI":"10.1016\/j.blre.2023.101165","article-title":"\u0391lpha-thalassemia: A practical overview","volume":"64","author":"KM Musallam","year":"2024","journal-title":"Blood Rev"},{"key":"pone.0352669.ref009","author":"SFDA","year":"2025"},{"issue":"10","key":"pone.0352669.ref010","article-title":"Right in time: Mitapivat for the treatment of anemia in \u03b1- and \u03b2-thalassemia","volume":"3","author":"KM Musallam","year":"2022","journal-title":"Cell Rep Med"},{"key":"pone.0352669.ref011","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1182\/blood-2022-169125","article-title":"Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat","volume":"140","author":"RF Grace","year":"2022","journal-title":"Blood"},{"issue":"2","key":"pone.0352669.ref012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.phoj.2024.03.003","article-title":"Mitapivat: New dawn in pyruvate kinase deficiency and beyond","volume":"9","author":"R Khurana","year":"2024","journal-title":"Pediatric Hematology Oncology Journal"},{"issue":"10","key":"pone.0352669.ref013","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14656566.2025.2514504","article-title":"Efficacy and safety of Mitapivat in sickle cell disease: a systematic review","volume":"26","author":"SR Chaudhary","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0352669.ref014","doi-asserted-by":"crossref","first-page":"100880","DOI":"10.1016\/j.imu.2022.100880","article-title":"Molecular modeling in drug discovery","volume":"29","author":"TI Adelusi","year":"2022","journal-title":"Informatics in Medicine Unlocked"},{"issue":"11","key":"pone.0352669.ref015","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/pharmaceutics16111414","article-title":"Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry","volume":"16","author":"N Alotaiq","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"pone.0352669.ref016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/ph18040559","article-title":"Computational Investigation of Montelukast and Its Structural Derivatives for Binding Affinity to Dopaminergic and Serotonergic Receptors: Insights from a Comprehensive Molecular Simulation","volume":"18","author":"N Alotaiq","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"pone.0352669.ref017","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.molstruc.2019.02.071","article-title":"3D-QSAR and molecular docking studies of aminopyrimidine derivatives as novel three-targeted Lck\/Src\/KDR inhibitors","volume":"1185","author":"W Xie","year":"2019","journal-title":"Journal of Molecular Structure"},{"key":"pone.0352669.ref018","first-page":"239","article-title":"In silico approaches which are used in pharmacy","volume":"14","author":"MBM Al-Mohaya","year":"2024","journal-title":"Journal of Applied Pharmaceutical Science"},{"issue":"2","key":"pone.0352669.ref019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.identj.2024.06.019","article-title":"In Silico Docking of Medicinal Herbs Against P. gingivalis for Chronic Periodontitis Intervention","volume":"75","author":"RS Saini","year":"2025","journal-title":"Int Dent J"},{"issue":"1","key":"pone.0352669.ref020","first-page":"1","article-title":"Molecular Dynamic Simulations and Molecular Docking as a Potential Way for Designed New Inhibitor Drug without Resistance","volume":"21","author":"J Aghajani","year":"2022","journal-title":"Tanaffos"},{"issue":"9","key":"pone.0352669.ref021","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/molecules24091714","article-title":"Revealing Drug-Target Interactions with Computational Models and Algorithms","volume":"24","author":"L Zhou","year":"2019","journal-title":"Molecules"},{"issue":"5","key":"pone.0352669.ref022","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s10753-025-02289-2","article-title":"Isoorientin ameliorates macrophage pyroptosis and atherogenesis by reducing KDM4A levels and promoting SKP1-Cullin1-F-box E3 ligase-mediated NLRP3 ubiquitination","volume":"48","author":"X Wang","year":"2025","journal-title":"Inflammation"},{"key":"pone.0352669.ref023","article-title":"Integrative Approaches to Uncover the Therapeutic Action of Huaiqihuang in Myocarditis: Network Pharmacology, Molecular Docking, and Molecular Dynamics","author":"Z Du","year":"2026","journal-title":"Curr Pharm Des"},{"key":"pone.0352669.ref024","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods","volume":"52","author":"B Zdrazil","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"pone.0352669.ref025","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1021\/acs.jcim.6b00174","article-title":"SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening","volume":"56","author":"V Zoete","year":"2016","journal-title":"J Chem Inf Model"},{"key":"pone.0352669.ref026","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1031","article-title":"The ChEMBL bioactivity database: an update","volume":"42","author":"AP Bento","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0352669.ref027","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12903-024-04343-1","article-title":"Dental biomaterials redefined: molecular docking and dynamics-driven dental resin composite optimization","volume":"24","author":"RS Saini","year":"2024","journal-title":"BMC Oral Health"},{"issue":"1","key":"pone.0352669.ref028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10856-024-06799-7","article-title":"In silico assessment of biocompatibility and toxicity: molecular docking and dynamics simulation of PMMA-based dental materials for interim prosthetic restorations","volume":"35","author":"RS Saini","year":"2024","journal-title":"J Mater Sci Mater Med"},{"key":"pone.0352669.ref029","volume-title":"BIOVIA Discovery Studio","author":"BIOVIA DS","year":"2024"},{"key":"pone.0352669.ref030","volume-title":"Origin(Pro)","author":"OriginLab","year":"2024"},{"key":"pone.0352669.ref031","volume-title":"Molecular Operating Environment (MOE)","year":"2025"},{"issue":"18","key":"pone.0352669.ref032","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802608786786624","article-title":"Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery","volume":"8","author":"S Vilar","year":"2008","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"pone.0352669.ref033","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/cryst14050441","article-title":"High Resolution Crystal Structure of the Pyruvate Kinase Tetramer in Complex with the Allosteric Activator Mitapivat\/AG-348","volume":"14","author":"X Han","year":"2024","journal-title":"Crystals"},{"issue":"15","key":"pone.0352669.ref034","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling","volume":"18","author":"N Guex","year":"1997","journal-title":"Electrophoresis"},{"issue":"1","key":"pone.0352669.ref035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pro.3289","article-title":"PDBsum: Structural summaries of PDB entries","volume":"27","author":"RA Laskowski","year":"2018","journal-title":"Protein Sci"},{"issue":"12","key":"pone.0352669.ref036","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4473","article-title":"PDBsum1: A standalone program for generating PDBsum analyses","volume":"31","author":"RA Laskowski","year":"2022","journal-title":"Protein Sci"},{"issue":"10","key":"pone.0352669.ref037","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/BF01114943","article-title":"L-Phenylalanine inhibition of muscle pyruvate kinase","volume":"2","author":"TN Palmer","year":"1982","journal-title":"Biosci Rep"},{"issue":"11","key":"pone.0352669.ref038","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1021\/bi400117q","article-title":"Identification of regions of rabbit muscle pyruvate kinase important for allosteric regulation by phenylalanine, detected by H\/D exchange mass spectrometry","volume":"52","author":"CB Prasannan","year":"2013","journal-title":"Biochemistry"},{"issue":"11","key":"pone.0352669.ref039","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1038\/s41596-024-01011-0","article-title":"The HADDOCK2.4 web server for integrative modeling of biomolecular complexes","volume":"19","author":"RV Honorato","year":"2024","journal-title":"Nat Protoc"},{"issue":"3","key":"pone.0352669.ref040","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2124","article-title":"PRODIGY: A Contact-based Predictor of Binding Affinity in Protein-protein Complexes","volume":"7","author":"A Vangone","year":"2017","journal-title":"Bio Protoc"},{"key":"pone.0352669.ref041","author":"P Panda","year":"2025"},{"issue":"1","key":"pone.0352669.ref042","doi-asserted-by":"crossref","first-page":"8146","DOI":"10.1038\/s41598-024-58599-2","article-title":"DFT\/TDDFT calculations of geometry optimization, electronic structure and spectral properties of clevudine and telbivudine for treatment of chronic hepatitis B","volume":"14","author":"DF Tegegn","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0352669.ref043","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00894-024-05884-6","article-title":"A B3LYP-D3 computational study of electronic, structural and torsional dynamic properties of mono-substituted naphthalenes: the effect of the nature and position of substituent","volume":"30","author":"A Benalia","year":"2024","journal-title":"J Mol Model"},{"key":"pone.0352669.ref044","doi-asserted-by":"crossref","first-page":"101391","DOI":"10.1016\/j.nxmate.2025.101391","article-title":"DFT-based investigation of structural, optoelectronic and molecular docking analysis of thiosemicarbazone derivatives","volume":"10","author":"ALD Yahyaoui","year":"2026","journal-title":"Next Materials"},{"issue":"2","key":"pone.0352669.ref045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/ct700248k","article-title":"Performance of B3LYP Density Functional Methods for a Large Set of Organic Molecules","volume":"4","author":"J Tirado-Rives","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"pone.0352669.ref046","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.physe.2016.03.010","article-title":"DFT (B3LYP\/LanL2DZ and B3LYP\/6311G+(d,p)) comparative vibrational spectroscopic analysis of organic\u2013inorganic compound bis(4-acetylanilinium) tetrachlorocuprate(II)","volume":"81","author":"A Abkari","year":"2016","journal-title":"Physica E: Low-dimensional Systems and Nanostructures"},{"issue":"11","key":"pone.0352669.ref047","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28114471","article-title":"How accurate can crystal structure predictions be for high-energy molecular crystals?","volume":"28","author":"X Bidault","year":"2023","journal-title":"Molecules"},{"issue":"27","key":"pone.0352669.ref048","doi-asserted-by":"crossref","first-page":"23532","DOI":"10.1021\/acsomega.2c02052","article-title":"Influence of End-Capped Modifications in the Nonlinear Optical Amplitude of Nonfullerene-Based Chromophores with a D-\u03c0-A Architecture: A DFT\/TDDFT Study","volume":"7","author":"M Khalid","year":"2022","journal-title":"ACS Omega"},{"issue":"11","key":"pone.0352669.ref049","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1021\/acs.jpclett.1c00094","article-title":"Elucidating the Electronic Structure of a Delayed Fluorescence Emitter via Orbital Interactions, Excitation Energy Components, Charge-Transfer Numbers, and Vibrational Reorganization Energies","volume":"12","author":"Z Pei","year":"2021","journal-title":"J Phys Chem Lett"},{"issue":"3","key":"pone.0352669.ref050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph18030410","article-title":"Computational Insights into the Antioxidant Activity of Luteolin: Density Functional Theory Analysis and Docking in Cytochrome P450 17A1","volume":"18","author":"ASN de Aguiar","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"pone.0352669.ref051","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"G Wolber","year":"2005","journal-title":"J Chem Inf Model"},{"issue":"7","key":"pone.0352669.ref052","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"S Pronk","year":"2013","journal-title":"Bioinformatics"},{"issue":"19","key":"pone.0352669.ref053","doi-asserted-by":"crossref","first-page":"10818","DOI":"10.3390\/ijms251910818","article-title":"Leveraging Therapeutic Proteins and Peptides from Lumbricus Earthworms: Targeting SOCS2 E3 Ligase for Cardiovascular Therapy through Molecular Dynamics Simulations","volume":"25","author":"N Alotaiq","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"pone.0352669.ref054","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/ijms26020462","article-title":"Evaluation of Structure Prediction and Molecular Docking Tools for Therapeutic Peptides in Clinical Use and Trials Targeting Coronary Artery Disease","volume":"26","author":"N Alotaiq","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"3","key":"pone.0352669.ref055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/pharmaceutics17030295","article-title":"Unveiling Pharmacological Mechanisms of Bombyx mori (Abresham), a Traditional Arabic Unani Medicine for Ischemic Heart Disease: An Integrative Molecular Simulation Study","volume":"17","author":"D Dermawan","year":"2025","journal-title":"Pharmaceutics"},{"key":"pone.0352669.ref056","volume-title":"The PyMOL Molecular Graphics System","author":"Schr\u00f6dinger","year":"2020"},{"issue":"13","key":"pone.0352669.ref057","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"EF Pettersen","year":"2004","journal-title":"J Comput Chem"},{"issue":"1","key":"pone.0352669.ref058","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0006-3495(03)74462-2","article-title":"Protocol for MM\/PBSA molecular dynamics simulations of proteins","volume":"85","author":"F Fogolari","year":"2003","journal-title":"Biophys J"},{"issue":"5","key":"pone.0352669.ref059","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"S Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"issue":"5","key":"pone.0352669.ref060","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/ci300064d","article-title":"Develop and test a solvent accessible surface area-based model in conformational entropy calculations","volume":"52","author":"J Wang","year":"2012","journal-title":"J Chem Inf Model"},{"key":"pone.0352669.ref061","doi-asserted-by":"crossref","unstructured":"Doni Dermawan FA, Nasr Eldin E, Alotaiq N. Therapeutic potential of earthworm-derived proteins: targeting NEDD4 for cardiovascular disease intervention. 2024;1:216\u201332.","DOI":"10.7324\/JAPS.2024.204162"},{"issue":"10","key":"pone.0352669.ref062","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","journal-title":"J Chem Theory Comput"},{"key":"pone.0352669.ref063","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"A Daina","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0352669.ref064","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci500588j","article-title":"DataWarrior: an open-source program for chemistry aware data visualization and analysis","volume":"55","author":"T Sander","year":"2015","journal-title":"J Chem Inf Model"},{"key":"pone.0352669.ref065","volume-title":"Schr\u00f6dinger release 2025-3: QikProp","author":"Schr\u00f6dinger","year":"2025"},{"issue":"11","key":"pone.0352669.ref066","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1021\/acs.accounts.5c00155","article-title":"ASKCOS: Open-Source, Data-Driven Synthesis Planning","volume":"58","author":"Z Tu","year":"2025","journal-title":"Acc Chem Res"},{"issue":"15","key":"pone.0352669.ref067","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4166","article-title":"Extraction of organic chemistry grammar from unsupervised learning of chemical reactions","volume":"7","author":"P Schwaller","year":"2021","journal-title":"Sci Adv"},{"key":"pone.0352669.ref068","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/B978-0-12-378630-2.00053-0","article-title":"Pyruvate Kinase","volume-title":"Encyclopedia of Biological Chemistry","author":"K Uyeda","year":"2013","edition":"2"},{"issue":"4","key":"pone.0352669.ref069","article-title":"Pyruvate kinase directly generates GTP in glycolysis, supporting growth and contributing to guanosine toxicity","volume":"16","author":"F She","year":"2025","journal-title":"mBio"},{"issue":"10","key":"pone.0352669.ref070","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/pro.3691","article-title":"An overview of structure, function, and regulation of pyruvate kinases","volume":"28","author":"N Schormann","year":"2019","journal-title":"Protein Sci"},{"issue":"2","key":"pone.0352669.ref071","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.abb.2011.09.012","article-title":"Allosteric regulation of phenylalanine hydroxylase","volume":"519","author":"PF Fitzpatrick","year":"2012","journal-title":"Arch Biochem Biophys"},{"issue":"14","key":"pone.0352669.ref072","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1074\/jbc.M115.709998","article-title":"Identification of the Allosteric Site for Phenylalanine in Rat Phenylalanine Hydroxylase","volume":"291","author":"S Zhang","year":"2016","journal-title":"J Biol Chem"},{"issue":"4076","key":"pone.0352669.ref073","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.179.4076.904","article-title":"Phenylketonuria: phenylalanine inhibits brain pyruvate kinase in vivo","volume":"179","author":"AL Miller","year":"1973","journal-title":"Science"},{"issue":"4","key":"pone.0352669.ref074","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1073\/pnas.63.4.1365","article-title":"Inhibition of human brain pyruvate kinase and hexokinase by phenylalanine and phenylpyruvate: possible relevance to phenylketonuric brain damage","volume":"63","author":"G Weber","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0352669.ref075","doi-asserted-by":"crossref","first-page":"117989","DOI":"10.1016\/j.ejmech.2025.117989","article-title":"Fluorescent binding assay for allosteric ligands of liver pyruvate kinase","volume":"298","author":"O Nilsson","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"17","key":"pone.0352669.ref076","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-023-01961-x","article-title":"Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults","volume":"83","author":"A Zhuang-Yan","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"pone.0352669.ref077","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2019.238865","article-title":"AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes","volume":"106","author":"MAE Rab","year":"2021","journal-title":"Haematologica"},{"issue":"24","key":"pone.0352669.ref078","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1182\/bloodadvances.2023011477","article-title":"One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study","volume":"7","author":"MJ van Dijk","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"pone.0352669.ref079","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.109","article-title":"Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease","volume":"8","author":"MJ van Dijk","year":"2024","journal-title":"Hemasphere"},{"issue":"6","key":"pone.0352669.ref080","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/bjh.20058","article-title":"Long-term efficacy and safety of mitapivat in non-transfusion-dependent \u03b1- or \u03b2-thalassaemia: An open-label phase 2 study","volume":"206","author":"KHM Kuo","year":"2025","journal-title":"Br J Haematol"},{"key":"pone.0352669.ref081","article-title":"Pyrukynd International non-proprietary name: mitapivat","author":"EMA","year":"2022"},{"issue":"11","key":"pone.0352669.ref082","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1021\/cr100242s","article-title":"Artificial receptors for the recognition of phosphorylated molecules","volume":"111","author":"AE Hargrove","year":"2011","journal-title":"Chem Rev"},{"key":"pone.0352669.ref083","doi-asserted-by":"crossref","first-page":"100223","DOI":"10.1016\/j.medidd.2025.100223","article-title":"Revolutionizing pharmacology: AI-powered approaches in molecular modeling and ADMET prediction","volume":"28","author":"I Pathan","year":"2025","journal-title":"Medicine in Drug Discovery"},{"key":"pone.0352669.ref084","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semcdb.2015.08.004","article-title":"Pyruvate kinase: Function, regulation and role in cancer","volume":"43","author":"WJ Israelsen","year":"2015","journal-title":"Semin Cell Dev Biol"},{"issue":"10","key":"pone.0352669.ref085","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"D Anastasiou","year":"2012","journal-title":"Nat Chem Biol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:48:39Z","timestamp":1786556919000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352669"}},"subtitle":[],"editor":[{"given":"Javed","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":85,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352669","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}